Corneal Cross-Linking for Keratoconus

This trial explores the safety and practicality of performing corneal cross-linking (a procedure to strengthen the eye's surface) in both eyes on the same day for individuals with keratoconus. This condition thins and shapes the cornea (the clear front part of the eye) into a cone, affecting vision. Participants will receive a treatment involving Epioxa™ and UV-A light, with additional oxygen, to determine if it stabilizes their vision. Individuals diagnosed with keratoconus in both eyes who have not previously undergone this treatment may be suitable candidates. As a Phase 4 trial, this research involves an FDA-approved treatment and aims to understand its benefits for a broader patient population.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that corneal cross-linking is generally safe for treating keratoconus. Studies have found that this procedure can halt the progression of the condition, and long-term evidence supports its high safety. For instance, over 80% of patients maintain stable vision even 10 years after treatment.

However, some risks exist. Common issues include pain, infection, delayed healing, and sensitivity to light. These side effects are usually temporary and resolve over time. In rare cases, the treatment might not work or could cause cloudiness in the cornea, the clear front part of the eye.

Unlike the standard corneal cross-linking treatments for keratoconus, which typically involve riboflavin eye drops and UV-A light, the Epioxa™ HD/Epioxa™ treatment combines UV-A irradiation with the O2n™ System and supplemental oxygen via Boost Goggles®. This approach enhances the cross-linking process by increasing oxygen availability, potentially leading to stronger and more effective corneal stabilization. Researchers are excited about this treatment because it could offer faster recovery and improved outcomes for patients, making it a promising advancement in managing keratoconus.

Research has shown that corneal cross-linking effectively treats keratoconus. Studies found that over 90% of patients experience good results, with the condition's progression halted. Long-term data from a five-year study indicated that this treatment maintains stability in most patients. Additional research confirms its safety and effectiveness in both adults and children. This procedure strengthens the cornea, helping to prevent further vision loss.²³⁶⁷⁸